Comparing ormeloxifene (a contraceptive) and medroxyprogesterone acetate (hormone supplement) in heavy periods patients

Effectiveness of ormeloxifene and medroxyprogesterone acetate in acute heavy menstrual bleeding - A Randomised control trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061782

Enrollment

Registered

2024-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period Health Condition 2: N924- Excessive bleeding in the premenopausal period

Interventions

Intervention1: Medroxyprogesterone Acetate: 60 MG twice a week for 3 months followed by 60 MG once a week for 1 month Control Intervention1: Medroxyprogesterone acetate: 10 MG twice a day till bleedin

Eligibility

Inclusion criteria

Inclusion criteria: Reproductive age group women

Exclusion criteria

Exclusion criteria: No structural abnormality

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of ormeloxifene and medroxyprogesterone acetate in acute heavy menstrual bleedingTimepoint: 4 months	—

Secondary

Measure	Time frame
To study the effect of ormeloxifene and medroxyprogesterone acetate on Endometrial thicknessTimepoint: 4 months	—

Countries

India

Contacts

Public ContactDr A Bupathy

Sri manakula vinayagar medical college and hospital

arunabup@yahoo.co.in8098250579

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026